107 related articles for article (PubMed ID: 2909757)
1. Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.
van Groeningen CJ; Peters GJ; Leyva A; Laurensse E; Pinedo HM
J Natl Cancer Inst; 1989 Jan; 81(2):157-62. PubMed ID: 2909757
[TBL] [Abstract][Full Text] [Related]
2. Reversal of 5-fluorouracil-induced toxicity by oral administration of uridine.
van Groeningen CJ; Peters GJ; Pinedo HM
Ann Oncol; 1993 Apr; 4(4):317-20. PubMed ID: 8518223
[TBL] [Abstract][Full Text] [Related]
3. Modulation of fluorouracil toxicity with uridine.
van Groeningen CJ; Peters GJ; Pinedo HM
Semin Oncol; 1992 Apr; 19(2 Suppl 3):148-54. PubMed ID: 1557641
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pharmacokinetic studies of prolonged administration of high-dose uridine intended for rescue from 5-FU toxicity.
van Groeningen CJ; Leyva A; Kraal I; Peters GJ; Pinedo HM
Cancer Treat Rep; 1986 Jun; 70(6):745-50. PubMed ID: 3731137
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of a modified, dose intensive FAMTX regimen (high dose 5-fluorouracil+doxorubicin+high dose methotrexate+leucovorin) with oral uridine rescue.
Schwartz GK; Christman K; Saltz L; Casper E; Quan V; Bertino J; Martin DS; Colofiore J; Kelsen D
Cancer; 1996 Nov; 78(9):1988-95. PubMed ID: 8909321
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Hidalgo M; Villalona-Calero MA; Eckhardt SG; Drengler RL; Rodriguez G; Hammond LA; Diab SG; Weiss G; Garner AM; Campbell E; Davidson K; Louie A; O'Neil JD; von Borstel R; Von Hoff DD; Rowinsky EK
J Clin Oncol; 2000 Jan; 18(1):167-77. PubMed ID: 10623707
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer.
Kelsen DP; Martin D; O'Neil J; Schwartz G; Saltz L; Sung MT; von Borstel R; Bertino J
J Clin Oncol; 1997 Apr; 15(4):1511-7. PubMed ID: 9193347
[TBL] [Abstract][Full Text] [Related]
8. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency.
Saif MW; Diasio RB
Cancer Chemother Pharmacol; 2016 Jul; 78(1):151-6. PubMed ID: 27278667
[TBL] [Abstract][Full Text] [Related]
9. In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.
Peters GJ; van Dijk J; Laurensse E; van Groeningen CJ; Lankelma J; Leyva A; Nadal JC; Pinedo HM
Br J Cancer; 1988 Mar; 57(3):259-65. PubMed ID: 3355763
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
11. Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I study.
Buzaid AC; Pizzorno G; Marsh JC; Ravikumar TS; Murren JR; Todd M; Strair RK; Poo WJ; Hait WN
Cancer Chemother Pharmacol; 1995; 36(5):373-8. PubMed ID: 7634378
[TBL] [Abstract][Full Text] [Related]
12. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
14. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
Klubes P; Cerna I
Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
[TBL] [Abstract][Full Text] [Related]
15. Protective effects of glutathione on 5-fluorouracil-induced myelosuppression in mice.
Kojima S; Takaba K; Kimoto N; Takeda T; Kakuni M; Mizutani M; Suzuki K; Sato H; Hara T
Arch Toxicol; 2003 May; 77(5):285-90. PubMed ID: 12734643
[TBL] [Abstract][Full Text] [Related]
16. Clinical and pharmacologic study of orally administered uridine.
van Groeningen CJ; Peters GJ; Nadal JC; Laurensse E; Pinedo HM
J Natl Cancer Inst; 1991 Mar; 83(6):437-41. PubMed ID: 1999851
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Ardalan B; Singh G; Silberman H
J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
[TBL] [Abstract][Full Text] [Related]
18. High-dose 5-fluorouracil with delayed uridine "rescue" in mice.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
Cancer Res; 1982 Oct; 42(10):3964-70. PubMed ID: 7104997
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.
Hainsworth JD; Burris HA; Erland JB; Thomas M; Greco FA
J Clin Oncol; 1998 Jun; 16(6):2164-8. PubMed ID: 9626217
[TBL] [Abstract][Full Text] [Related]
20. Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil.
Bagrij T; Kralovanszky J; Gyergyay F; Kiss E; Peters GJ
Anticancer Res; 1993; 13(3):789-93. PubMed ID: 8317913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
